Mansour A Alharbi, Fahad Aldosari, Ahmed Hasan Althobaiti, Faris M Abdullah, Salman Aljarallah, Nuha M Alkhawajah, Miteb Alanazi, Yazed AlRuthia
INTRODUCTION: The advent of new disease-modifying therapies (DMTs), such as monoclonal antibodies (mAbs), resulted in significant changes in the treatment guidelines for Multiple sclerosis (MS) and improvement in the clinical outcomes. However, mAbs, such as rituximab, natalizumab, and ocrelizumab, are expensive with variable effectiveness rates. Thus, the present study aimed to compare the direct medical cost and consequences (e.g., clinical relapse, disability progression, and new MRI lesions) between rituximab and natalizumab in managing relapsing-remitting multiple sclerosis (RRMS) in Saudi Arabia...
May 26, 2023: BMC Health Services Research